LIFE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LIFE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. aTyr Pharma's forward rate of return for was 0.00%.
The historical rank and industry rank for aTyr Pharma's Forward Rate of Return (Yacktman) % or its related term are showing as below:
During the past 11 years, aTyr Pharma's highest Forward Rate of Return was 20.00. The lowest was 19.77. And the median was 20.00.
Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
The historical data trend for aTyr Pharma's Forward Rate of Return (Yacktman) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Forward Rate of Return (Yacktman) % | Get a 7-Day Free Trial | - | - | - | - | - |
aTyr Pharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Forward Rate of Return (Yacktman) % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, aTyr Pharma's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, aTyr Pharma's Forward Rate of Return (Yacktman) % distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's Forward Rate of Return (Yacktman) % falls into.
Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
aTyr Pharma's Forward Rate of Return of Mar. 2024 is
Forward Rate of Return | = | Normalized Free Cash Flow | / | Price | + | 5-Year EBITDA Growth Rate |
= | 0 | / | 1.95 | + | 0 | |
= | 0.00 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma (NAS:LIFE) Forward Rate of Return (Yacktman) % Explanation
Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.
Be Aware
In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.
Thank you for viewing the detailed overview of aTyr Pharma's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sanjay Shukla | officer: Chief Medical Officer | C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121 |
Paul Schimmel | director | 88 SIDNEY ST, CAMBRIDGE MA 02139 |
Jill Marie Broadfoot | officer: Chief Financial Officer | 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Sara Zaknoen | director | C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121 |
John K Clarke | director | C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542 |
Nancy Krueger | officer: See Remarks | C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Svetlana Lucas | director | 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Jane A Gross | director | 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121 |
John Mendlein | director, officer: CEO and Executive Chairman | |
Ecor1 Capital Fund Qualified, L.p. | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Ashraf Amanullah | officer: Vice President, Manufacturing | C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
John T Blake | officer: Vice President, Finance | C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342 |
Timothy P Coughlin | director | 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075 |
Jeffrey S. Hatfield | director | 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
David John King | officer: See Remarks | 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
From GuruFocus
By Value_Insider Value_Insider • 11-10-2022
By sperokesalga sperokesalga • 05-25-2023
By sperokesalga sperokesalga • 05-09-2023
By sperokesalga sperokesalga • 06-09-2023
By sperokesalga sperokesalga • 03-02-2023
By Marketwired • 06-22-2023
By sperokesalga sperokesalga • 04-17-2023
By sperokesalga sperokesalga • 02-09-2023
By Stock market mentor Stock market mentor • 01-31-2023
By Marketwired • 11-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.